Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview 8 Therapeutics Development 9 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Stage of Development 9 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Therapy Area 10 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Indication 11 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Companies 15 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Universities/Institutes 18 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Companies Involved in Therapeutics Development 26 AbbVie Inc 26 Affibody AB 27 Anacor Pharmaceuticals, Inc. 28 Apexigen, Inc. 29 Cell Medica Limited 30 Handok Inc. 31 Immune Response BioPharma, Inc. 32 Novartis AG 33 Omnitura Therapeutics Inc. 34 Opsona Therapeutics Limited 35 Peptinov SAS 36 R-Pharm 37 Regeneron Pharmaceuticals Inc 38 TWi Pharmaceuticals, Inc. 39 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Drug Profiles 40 ABT-981 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 AN-4161 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 APX-002 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 canakinumab - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 diacerein - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 DLX-2323 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 DLX-2681 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 HL-2351 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 IR-1000 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 IR-1002 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 IR-888 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 melittin - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 OMN-54 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 PPV-01 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 rilonacept - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 RPH-104 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecule Inflammasome Modulator Programme - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Dormant Projects 67 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Discontinued Products 72 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Featured News & Press Releases 75 Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment 75 Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab 75 Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes 76 Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 76 Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 77 Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 78 Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting 79 Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes 79 Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia 80 Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan 80 Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 81 Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan 81 Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States 81 Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States 82 Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States 82 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Assessment by Monotherapy/Combination Products, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Pipeline by AbbVie Inc, H2 2016 26 Pipeline by Affibody AB, H2 2016 27 Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 28 Pipeline by Apexigen, Inc., H2 2016 29 Pipeline by Cell Medica Limited, H2 2016 30 Pipeline by Handok Inc., H2 2016 31 Pipeline by Immune Response BioPharma, Inc., H2 2016 32 Pipeline by Novartis AG, H2 2016 33 Pipeline by Omnitura Therapeutics Inc., H2 2016 34 Pipeline by Opsona Therapeutics Limited, H2 2016 35 Pipeline by Peptinov SAS, H2 2016 36 Pipeline by R-Pharm, H2 2016 37 Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 38 Pipeline by TWi Pharmaceuticals, Inc., H2 2016 39 Dormant Projects, H2 2016 67 Dormant Projects (Contd..1), H2 2016 68 Dormant Projects (Contd..2), H2 2016 69 Dormant Projects (Contd..3), H2 2016 70 Dormant Projects (Contd..4), H2 2016 71 Discontinued Products, H2 2016 72 Discontinued Products (Contd..1), H2 2016 73 Discontinued Products (Contd..2), H2 2016 74
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
